Cerevance Media Center

Current News

February 15, 2024

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters. In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist”

READ FULL

November 13, 2023

Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease

Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease

READ FULL

September 19, 2023

Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.

READ FULL

August 28, 2023

Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023

Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

February 22, 2024

Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference

Date:
Monday, March 4, 2024
Time:
Scheduled Meetings
Location:
Boston, MA
Media:
Scheduled Meetings
Read full

December 5, 2023

Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference

Date:
Thursday, December 14, 2023
Time:
1:10 – 1:40 pm ET
Location:
Washington, DC
Media:
Fireside Chat
Read full

November 28, 2023

Cerevance Announces Presentation at the 34th International Symposium on ALS/MND

Date:
Thursday, December 7, 2023
Time:
5:45 – 7:45pm CET
Location:
Basel, Switzerland
Media:
Poster
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

February 12, 2024

Discovery and First-time Disclosure of CVN766, an Exquisitely Selective Orexin 1 Receptor Antagonist

Glen, A., Bürli, R.W., Livermore, D., Buffham, W., Merison, S., Rowland, A.E., Newman, R., Fieldhouse, C., Miller, D.J., Dawson, L.A., Matthews, K., Carlton, M.B., Brice, N.L.

view

December 25, 2023

NETSseq Advances the Understanding of Neuronal Vulnerability in AD Progression Facilitating the Identification of Novel Therapeutic Targets at the Single Cell Type Level

Bayraktar, G.,Christie, L., Brice, N., Xu, X., Stirparo, G., Lizio, M., Powell, J., Cadwalladr, D., Cheung, T., Sheardown, S., Page, K., Dawson, L.A.,Carlton, M.

view

November 15, 2023

NETSseq Platform Identifies the Astrocyte Specific Potassium Channel KCNJ10 (kir4.1) as a Target for the Potential Treatment of Neurodegenerative Diseases

Bender, C.L., Harvey, J.R.M., Burley, R.,Ossola, B., Pickford, P.J., Barker, D.F., Mulligan, V.J., Page, K.J., Carlton, M.L.N, Brice, N.L., Dawson, L.A.

view

May 30, 2023

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, & W9 Pharmacokinetic Study of Escalating Single & Multiple Doses of CVN766, an OX1R Highly Selective Antagonist, in Healthy Subjects

Vitolo, O.

view

May 9, 2023

Uncovering Novel Cell Types and Therapeutic Targets in Alzheimer's Disease Using Cerevance’s NETSseq Platform and Analysis

Stirparo, G., Xu, X., Lizio, M., Powell, J., Cheung, T., Bayraktar, G., Christie, L., Roberts, M., Crane, G., Cadwalladr, D., Lawrence, J., Sheardown, S., Ossola, B., Brice, N.L., Page, K., Dawson, L.A., Carlton, M.B.

view

May 2, 2023

Phase 1 Study of CVN424, a Novel GPR6 Inverse Agonist

Margolin, D.H., Brice, N.L., Davidson, A.M., Matthews, K.L., Carlton, M.B.

view